Latona Life Sciences Fact Sheet
Latona Life Sciences,Inc., founded in 2007, has its headquarters in Scottsdale, AZ. Latona is a privately-held specialty pharmaceutical company dedicated to the development and commercialization of immune-mediated diseases.
Latona’s core management team includes executives with successful backgrounds in the pharmaceutical, biotech¸ medical device and diagnostics industry, including experience with startup companies, product development and FDA .
Latona has been granted Orphan Drug Status for Oralgam™ for Juvenile Idiopathic Arthritis (JIA), autistic enterocolitis and dermatomyositis.
Oralgam, Latona’s lead product candidate, has shown efficacy in the treatment of JIA in a phase II clinical trial in an extension of the IND. Latona’s therapeutic strategy centers on the fact that orally administered antibodies act against the initiation, as well as the harmful continuous feedback, of immune-mediated disease processes. Rather than treating inflammation as a manifestation of autoimmunity, Dr. Richard Weisbart, the inventor of Oralgam proposed the use of oral gamma globulin as a replacement therapy for diseases caused by immune deficiency of the gastrointestinal tract.
Latona is in the process of evaluating licensing opportunities for additional therapeutic assets and has identified licensing opportunities.
Oralgam is a registered trademark of Latona Life Sciences, Inc.